Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Express Scripts
Cipla
Deloitte
Medtronic
Cerilliant
Queensland Health
Covington

Generated: July 19, 2018

DrugPatentWatch Database Preview

Sovereign Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SOVEREIGN PHARMS, and when can generic versions of SOVEREIGN PHARMS drugs launch?

SOVEREIGN PHARMS has two approved drugs.

There is one US patent protecting SOVEREIGN PHARMS drugs.

Summary for Sovereign Pharms
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Sovereign Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sovereign Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET;ORAL 204900-003 Jul 23, 2015 DISCN No No ➤ Sign Up ➤ Sign Up
Sovereign Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET;ORAL 204900-001 Jul 23, 2015 DISCN No No ➤ Sign Up ➤ Sign Up
Sovereign Pharms AMLODIPINE BESYLATE amlodipine besylate TABLET;ORAL 204900-002 Jul 23, 2015 DISCN No No ➤ Sign Up ➤ Sign Up
Sovereign Pharms OBREDON guaifenesin; hydrocodone bitartrate SOLUTION;ORAL 205474-001 Nov 14, 2014 DISCN Yes No 9,549,907 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Sovereign Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,808,431 Immediate release oral guaifenesin solution ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Accenture
US Army
Chinese Patent Office
Queensland Health
Deloitte
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.